Hero Image

PSA Levels in Advanced Prostate Cancer - What the Numbers Mean and Current Treatment Options

For men living with advanced prostate cancer, the PSA test plays a different role than it does in routine screening. Instead of flagging possible cancer, it becomes one of the main ways doctors track whether treatment is working and when it may be time to change course. This guide explains how PSA levels are used in locally advanced and metastatic prostate cancer, why some advanced cancers show a low PSA, and which treatment approaches are commonly discussed at each stage.

What "Advanced" Prostate Cancer Means

Doctors generally use "advanced" to describe prostate cancer that has grown beyond the prostate gland. That includes two broad situations:

  • Locally advanced prostate cancer has spread just outside the prostate, for example into the surrounding tissue or the seminal vesicles, but not to distant parts of the body.
  • Metastatic prostate cancer, often called stage 4, has spread to lymph nodes farther away or to other organs, most often the bones.

Prostate cancer that comes back after surgery or radiation is also often grouped with advanced disease, because a rising PSA may be the first sign of recurrence even before anything shows up on a scan.

How PSA Is Used Once Prostate Cancer Is Advanced

After diagnosis, PSA works mainly as a tracking tool. Doctors look less at any single number and more at how PSA changes over time:

  • Response to treatment. A falling PSA after starting therapy usually means the treatment is having an effect. How low PSA drops, and how quickly, can help doctors judge the response.
  • PSA after surgery or radiation. After the prostate is removed, PSA should fall to a very low or undetectable level, so a confirmed rise can signal recurrence. After radiation, PSA usually falls more slowly, and doctors compare later results with the lowest level reached.
  • PSA doubling time. This is how long it takes PSA to double. A shorter doubling time generally suggests faster-growing cancer and can affect how soon treatment is started or changed.
  • Rising PSA during hormone therapy. If PSA climbs even though testosterone has been lowered, the cancer may have become castration-resistant, which opens a different set of treatment options.

When Advanced Prostate Cancer Has a Low PSA

Most prostate cancers produce PSA, but not all do. Some less common, often more aggressive forms, such as neuroendocrine or small cell prostate cancer, can make little PSA even when the disease is spreading. In these cases, a low PSA can be falsely reassuring.

That's why doctors usually pair PSA with imaging and symptoms when monitoring advanced disease. PSMA PET scans, which detect a protein found on many prostate cancer cells, can locate cancer that standard CT and bone scans may miss. If symptoms or scans don't match a low PSA, a biopsy of a metastasis may be recommended to understand the type of cancer involved.

Treatment Options for Locally Advanced Prostate Cancer

Locally advanced prostate cancer is often treated with the goal of controlling it for the long term. Common approaches include:

  • Radiation therapy combined with hormone therapy (androgen deprivation therapy, or ADT), often for a set period of months to a few years.
  • Surgery to remove the prostate in selected men, sometimes followed by radiation.
  • Additional hormone-targeting medicines for some higher-risk cases.

The right combination depends on how far the cancer has spread locally, PSA level, Gleason score or grade group, and overall health.

Treatment Options for Stage 4 and Metastatic Prostate Cancer

For metastatic prostate cancer, hormone therapy that lowers testosterone is usually the foundation of treatment. What's added on top depends on whether the cancer still responds to low testosterone:

Hormone-sensitive metastatic prostate cancer

When the cancer still responds to testosterone-lowering therapy, doctors commonly add a newer hormone-targeting medicine (such as abiraterone, enzalutamide, apalutamide or darolutamide), chemotherapy with docetaxel, or in some cases both. Radiation to the prostate may also be considered when the amount of metastatic disease is low.

Castration-resistant metastatic prostate cancer

When PSA or scans show the cancer is growing despite low testosterone, options can include:

  • A different hormone-targeting medicine, if one hasn't been used yet
  • Chemotherapy, such as docetaxel or cabazitaxel
  • PARP inhibitors for men whose tumors have certain gene changes, such as BRCA mutations, which is why genetic testing is often recommended in advanced prostate cancer
  • PSMA-targeted radioligand therapy, which delivers radiation directly to cancer cells that carry the PSMA protein
  • Radium-223 for cancer that has spread mainly to the bones and is causing symptoms
  • Clinical trials of newer approaches

Metastasis-directed therapy (MDT)

For men with only a few spots of spread, sometimes called oligometastatic disease, doctors may discuss metastasis-directed therapy. This uses focused treatments, most often precisely targeted radiation, aimed at each visible spot. It's an active area of research, and whether it fits depends on how many metastases there are, where they are and what other treatment is planned. Ask whether you may be a candidate and whether a clinical trial is available.

Advanced Prostate Cancer in Men in Their 70s and 80s

Age alone doesn't decide treatment. Many men in their 70s and 80s with advanced prostate cancer are good candidates for hormone therapy and newer medicines, while others may prioritize fewer side effects. Doctors increasingly use an assessment of overall health, other medical conditions and daily function, rather than age by itself, to guide recommendations. Some treatments can affect bone strength, heart health or energy levels, so those risks are weighed alongside the benefits.

Questions to Ask Your Care Team

  • Is my cancer locally advanced or metastatic, and where has it spread?
  • Is it still hormone-sensitive, or has it become castration-resistant?
  • What is my PSA trend, and how often will it be checked?
  • Would a PSMA PET scan change my treatment plan?
  • Should I have genetic testing of my tumor or my blood?
  • Am I a candidate for metastasis-directed therapy or a clinical trial?
  • What side effects should I watch for, and how are they managed?

If you're still in the early stages of evaluation, our guide to prostate cancer symptoms, testing and treatment covers how diagnosis works, and our article on when to see a urologist explains how to find specialist care.

Frequently Asked Questions

What PSA level is considered high in advanced prostate cancer?

There's no single cutoff. In advanced disease, doctors focus on how PSA changes over time and how it responds to treatment, rather than comparing it with a screening range.

Can PSA go down to zero during treatment?

PSA can become very low or undetectable during effective treatment, especially after surgery or with hormone therapy. Doctors continue to monitor it because a later rise can be an early sign that the cancer is becoming active again.

Is stage 4 prostate cancer treatable?

Yes. Although metastatic prostate cancer is generally not considered curable, many treatments can control it, often for years, and new options continue to be developed.

This article is for general information only and is not medical advice. Treatment decisions depend on individual circumstances, so discuss your PSA results and options with your doctor.